Rakovina advances synthesis of PARP1-selective inhibitors
Jan. 7, 2025
Rakovina Therapeutics Inc. has announced the successful synthesis of novel small-molecule drug candidates designed under the company’s artificial intelligence (AI) platform collaboration.